Senti Bio partners with Celest for SENTI-301A development in China; up to $156M milestones

Senti Biosciences, Inc.

Celest to lead clinical development and manufacturing of SENTI-301A in mainland China; first patient expected 1H 2024.
Senti Bio retains all commercialization rights outside mainland China, Hong Kong, Macau, and Taiwan.
Senti eligible for up to $156M in milestone payments plus tiered royalties on potential sales.
SENTI-301A is an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing hepatocellular carcinoma.
Pilot trial will enroll 9 patients across two dose cohorts to assess safety and efficacy.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Senti Biosciences, Inc. entered into Collaboration and Option Agreement with Celest Therapeutics (Shanghai) Co. Ltd. (effective 2023-11-06).

Action: entry
Agreement: collaboration
Counterparty: Celest Therapeutics (Shanghai) Co. Ltd.
Effective: 2023-11-06

Exact text from the filing

On November 6, 2023, Senti Biosciences, Inc. (the “ Company ”) entered into a Collaboration and Option Agreement (the “ Agreement ”) with Celest Therapeutics (Shanghai) Co. Ltd.

View on SEC.gov

43 material agreements filed in the last 30 days. Browse all material agreements →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-23-000119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.